Shattuck Labs
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 75
- Market Cap
- $168M
- Website
- http://www.shattucklabs.com
Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers
- Conditions
- Platinum-resistant Ovarian CancerPlatinum-Resistant Fallopian Tube CarcinomaEpithelial Ovarian CancerPlatinum-Resistant Primary Peritoneal CarcinomaFallopian Tube CancerOvarian CancerPrimary Peritoneal Carcinoma
- Interventions
- Drug: Pegylated Liposomal Doxorubicin + SL-172154Drug: Mirvetuximab + SL-172154
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Shattuck Labs, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT05483933
- Locations
- 🇪🇸
Hospital Universitario Fundacion Jimenez Diaz START Madrid-FJD- Unidad de Ensayos Fase I, Madrid, Spain
🇪🇸Hospital Universitario Virgen de la Arrixaca. Servicio de Oncología Ctra. Madrid-Cartagena, s/n, Murcia, Spain
🇺🇸University of Arkansas for Medical sciences, Little Rock, Arkansas, United States
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- Drug: SL-172154
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Shattuck Labs, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT05275439
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Baylor Scott & White Research Institute, Dallas, Texas, United States
Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
- Conditions
- Squamous Cell Carcinoma of Head and NeckCutaneous Squamous Cell Carcinoma
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Shattuck Labs, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04502888
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer
- Conditions
- Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
- Interventions
- Drug: SL-172154
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Shattuck Labs, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04406623
- Locations
- 🇺🇸
START Mountain Region, West Valley City, Utah, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
🇺🇸Stephenson Cancer Center at Oklahoma University, Oklahoma City, Oklahoma, United States
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
- Conditions
- Non Small Cell Lung CancerUrothelial CarcinomaSquamous Cell Carcinoma of the AnusSquamous Cell Carcinoma of the CervixSquamous Cell Carcinoma of the SkinRenal Cell CarcinomaHodgkin LymphomaMismatch Repair Deficient or MSI-High Solid TumorsSquamous Cell Carcinoma of the Head and NeckGastric Adenocarcinoma
- Interventions
- Drug: SL-279252
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Shattuck Labs, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT03894618
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸The Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇪🇸Vall d'Hebron Institut D' Oncologia, Barcelona, Spain